BRPI0813729B8 - métodos de preparação de massas celulares de cardiomiócitos purificados derivados de células-tronco pluripotentes e de uma película de massas celulares de cardiomiócitos, bem como dispositivo médico e uso das referidas massas celulares - Google Patents

métodos de preparação de massas celulares de cardiomiócitos purificados derivados de células-tronco pluripotentes e de uma película de massas celulares de cardiomiócitos, bem como dispositivo médico e uso das referidas massas celulares

Info

Publication number
BRPI0813729B8
BRPI0813729B8 BRPI0813729A BRPI0813729A BRPI0813729B8 BR PI0813729 B8 BRPI0813729 B8 BR PI0813729B8 BR PI0813729 A BRPI0813729 A BR PI0813729A BR PI0813729 A BRPI0813729 A BR PI0813729A BR PI0813729 B8 BRPI0813729 B8 BR PI0813729B8
Authority
BR
Brazil
Prior art keywords
cell masses
cardiomyocytes
pluripotent stem
stem cells
purified
Prior art date
Application number
BRPI0813729A
Other languages
English (en)
Inventor
Hattori Fumiyuki
Fukuda Keiichi
Original Assignee
Univ Keio
Asubio Pharma Co Ltd
Heartseed Inc
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Keio, Asubio Pharma Co Ltd, Heartseed Inc, Daiichi Sankyo Co Ltd filed Critical Univ Keio
Publication of BRPI0813729A2 publication Critical patent/BRPI0813729A2/pt
Publication of BRPI0813729B1 publication Critical patent/BRPI0813729B1/pt
Publication of BRPI0813729B8 publication Critical patent/BRPI0813729B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3826—Muscle cells, e.g. smooth muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/04—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from germ cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

MÉTODO PARA CONSTRUÇÃO DE MASSAS DE CÉLULAS MIOCÁRDICAS E USO DA MASSA DE CÈLULA MIOCÁRDICA. A presente invenção refere-se a melhorara da taxa de enxertia pós-transplante de cardiomiócitos que foram purificados em tal proporção que eles estão livres de não-cardiomiócitos e quaisquer componentes derivados de outras espécies. Para solucionar o problema, os presentes inventores estudaram a possibilidade de construir massas celulares de cardiomiócitos purificados. Como resultado, eles mostram que o problema declarado poderia ser solucionado pelo fornecimento de um método de preparação de massas celulares de cardiomiócitos derivados de células-tronco pluripotentes, caracterizado pelo fato de que as massas celulares de células agregadas que contêm os cardiomiócitos que foram diferenciados e induzidos a partir de células-tronco pluripotentes, que foram dispersos como células isoladas para se obter, dessa maneira, cardiomiócitos purificados, que forma cultivados depois em um meio de cultura sob condições sem soro, possam ser reagregados.
BRPI0813729A 2007-07-31 2008-07-31 métodos de preparação de massas celulares de cardiomiócitos purificados derivados de células-tronco pluripotentes e de uma película de massas celulares de cardiomiócitos, bem como dispositivo médico e uso das referidas massas celulares BRPI0813729B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2007-200246 2007-07-31
JP2007200246 2007-07-31
JP2008-046772 2008-02-27
JP2008046772 2008-02-27
PCT/JP2008/064168 WO2009017254A1 (ja) 2007-07-31 2008-07-31 心筋細胞の細胞塊作製方法及び当該心筋細胞塊の用途

Publications (3)

Publication Number Publication Date
BRPI0813729A2 BRPI0813729A2 (pt) 2014-12-30
BRPI0813729B1 BRPI0813729B1 (pt) 2019-04-02
BRPI0813729B8 true BRPI0813729B8 (pt) 2022-09-27

Family

ID=40304474

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813729A BRPI0813729B8 (pt) 2007-07-31 2008-07-31 métodos de preparação de massas celulares de cardiomiócitos purificados derivados de células-tronco pluripotentes e de uma película de massas celulares de cardiomiócitos, bem como dispositivo médico e uso das referidas massas celulares

Country Status (11)

Country Link
US (2) US9109205B2 (pt)
EP (1) EP2172542B1 (pt)
JP (1) JP5523830B2 (pt)
KR (2) KR20100040276A (pt)
CN (1) CN101711277B (pt)
AU (1) AU2008283255B2 (pt)
BR (1) BRPI0813729B8 (pt)
CA (1) CA2690610C (pt)
IL (1) IL203404A (pt)
RU (1) RU2467066C2 (pt)
WO (1) WO2009017254A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5674046B2 (ja) * 2009-09-30 2015-02-18 国立大学法人鳥取大学 新規ペースメーカ細胞
CA2777552C (en) * 2009-10-19 2019-05-21 Cellular Dynamics International, Inc. Cardiomyocyte production
JPWO2011071118A1 (ja) * 2009-12-09 2013-04-22 国立大学法人京都大学 ニトロビンを含む多能性幹細胞の心筋細胞への分化促進剤
EP2582792B1 (en) * 2010-06-18 2018-10-31 FUJIFILM Cellular Dynamics, Inc. Cardiomyocyte medium with dialyzed serum
EP2584029B1 (en) * 2010-07-29 2017-06-21 Terumo Kabushiki Kaisha Sheet-shaped cell culture dissociation system
WO2015175534A2 (en) * 2014-05-13 2015-11-19 The Regents Of The University Of Michigan Compositions and methods employing stem cell-derived cardiomyocytes
SG11201700023WA (en) 2014-07-16 2017-02-27 Heartseed Inc New undifferentiated stem cell removal and myocardial purification and refinement culture medium
WO2016052657A1 (ja) * 2014-09-30 2016-04-07 国立研究開発法人産業技術総合研究所 万能性幹細胞の培養方法
WO2016076368A1 (ja) * 2014-11-12 2016-05-19 テルモ株式会社 心筋細胞シート
CN104830761A (zh) * 2015-06-04 2015-08-12 黑龙江省瑞生会生物技术开发有限公司 一种培养心肌细胞的无血清培养基
EP3150696A1 (en) 2015-09-30 2017-04-05 Shibuya Corporation Apparatus for producing cell mass sheet and method for producing cell mass sheet
JP6593589B2 (ja) * 2015-09-30 2019-10-23 澁谷工業株式会社 細胞塊シートの作製方法および細胞塊シート
EP3162890A1 (en) 2015-10-29 2017-05-03 Shibuya Corporation Method and apparatus for producing cell mass structure
CN109153973A (zh) * 2016-03-18 2019-01-04 国立大学法人京都大学 用于冷冻多能干细胞来源心肌细胞的聚集体的方法
WO2018074457A1 (ja) 2016-10-17 2018-04-26 学校法人慶應義塾 未分化幹細胞除去剤、及び未分化幹細胞除去方法
JP6426327B2 (ja) 2016-11-01 2018-11-21 テルモ株式会社 接着状態の細胞培養物の改変方法
JP2018093823A (ja) 2016-12-15 2018-06-21 Ｈｅａｒｔｓｅｅｄ株式会社 未分化幹細胞除去剤及び未分化幹細胞除去方法
WO2018164098A1 (ja) * 2017-03-06 2018-09-13 国立大学法人大阪大学 心臓線維化モデルとして用いられる細胞集団、その製造方法、それを利用したスクリーニング方法及び心臓線維化モデルの評価方法、並びに心臓線維化モデルの評価システム
JPWO2018164098A1 (ja) * 2017-03-16 2020-01-16 国立大学法人大阪大学 心臓線維化モデルとして用いられる細胞集団、その製造方法、それを利用したスクリーニング方法及び心臓線維化モデルの評価方法、並びに心臓線維化モデルの評価システム
CN106957815B (zh) * 2017-03-16 2021-05-07 杨涛 一种用于人类多潜能干细胞的无血清培养基的配方
CN110506109B (zh) * 2017-06-05 2024-03-12 泰尔茂株式会社 细胞培养物的制造方法
EP3819373A4 (en) * 2018-07-06 2022-05-18 Myoridge Co. Ltd. CELL LAYER PREPARATION METHOD, HEART MUSCLE LAYER AND KIT FOR MAKING A HEART MUSCLE LAYER
JP7038368B2 (ja) * 2019-11-21 2022-03-18 日本毛織株式会社 細胞集合体、その製造方法、その作製キット、及びそれを用いた化合物の評価方法
KR102188256B1 (ko) * 2019-12-02 2020-12-08 주식회사 티앤알바이오팹 동결보관 및 저산소 조건에서의 생존율을 향상시키는 심근세포 응집체 제작 기술
JPWO2022014622A1 (pt) * 2020-07-14 2022-01-20
CN112657051B (zh) * 2020-12-25 2023-08-04 上海交通大学医学院附属上海儿童医学中心 一种基于共轭同轴静电纺丝技术的生物型心室辅助泵及其制备方法
WO2022210824A1 (ja) 2021-03-31 2022-10-06 株式会社カネカ 心筋細胞塊の製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0372872A (ja) * 1988-07-12 1991-03-28 Bio Kagaku Kenkyusho:Kk 無血清培地及びそれを用いた哺乳類細胞の培養法
SG141296A1 (en) * 2002-05-17 2008-04-28 Sinai School Medicine Mesoderm and definitive endoderm cell populations
WO2005033298A1 (ja) * 2003-10-03 2005-04-14 Keiichi Fukuda 幹細胞から心筋細胞を分化誘導する方法
CN1969040B (zh) * 2004-03-19 2014-12-10 阿斯特利亚斯生物治疗股份公司 制备适合用于再生医学的高纯度心肌细胞的方法
US20050214938A1 (en) 2004-03-26 2005-09-29 Gold Joseph D Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function
US7452718B2 (en) * 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
CA2577201C (en) * 2004-08-27 2016-02-09 Daiichi Asubio Pharma Co., Ltd. A method of selecting a cardiomyocyte using intracellular mitochondria as an indicator

Also Published As

Publication number Publication date
JP5523830B2 (ja) 2014-06-18
AU2008283255B2 (en) 2013-07-04
KR20100040276A (ko) 2010-04-19
WO2009017254A1 (ja) 2009-02-05
EP2172542A4 (en) 2011-12-21
RU2467066C2 (ru) 2012-11-20
US20150366918A1 (en) 2015-12-24
IL203404A (en) 2014-08-31
AU2008283255A1 (en) 2009-02-05
BRPI0813729B1 (pt) 2019-04-02
CA2690610C (en) 2023-03-28
EP2172542A1 (en) 2010-04-07
CA2690610A1 (en) 2009-02-05
JPWO2009017254A1 (ja) 2010-10-28
CN101711277A (zh) 2010-05-19
KR101582483B1 (ko) 2016-01-06
CN101711277B (zh) 2018-06-19
EP2172542B1 (en) 2017-03-22
KR20130090423A (ko) 2013-08-13
US20100189699A1 (en) 2010-07-29
BRPI0813729A2 (pt) 2014-12-30
US10918671B2 (en) 2021-02-16
RU2010101091A (ru) 2011-07-20
US9109205B2 (en) 2015-08-18

Similar Documents

Publication Publication Date Title
AU2019268194A1 (en) Cell culture system
IL273159B1 (en) A culture medium preparation, and a method for culturing cells or tissues by using the preparation
BR112015021993A8 (pt) polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular
BR112015019950A2 (pt) Método para gerar linhagem de células-tronco embrionárias (es) de rato, e, cultura in vitro
IN2014DN08862A (pt)
EA202091407A1 (ru) Состав бессывороточной среды для культивирования клеток и способы его применения
BR112015022770A8 (pt) meio e sistema de cultivo da célula livre de xenógeno, livre de albumina, forma concentrada, métodos de diferenciação de células-tronco pluripotentes humanas, para a produção de mesenquimoangioblastos e sistema definido de cultivo da célula para diferenciação hematoendotelial das células- tronco pluripotentes humanas
JP2017131682A5 (pt)
PH12014501407A1 (en) Plant artificial seeds and methods for the production thereof
SG170021A1 (en) Compositions and methods useful for culturing differentiable cells
BR112016002040A2 (pt) meio condicionado derivado de células estromais, método de obtenção das ditas composições de meio condicionado, formulações e aplicações dos mesmos
BR112013004514A2 (pt) diferenciação das células-tronco embrionárias humanas
WO2013006474A3 (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
RU2009130630A (ru) Способ получения мезенхимной клетки, способ получения зуба и мезенхимная клетка для формирования зуба
EA201490945A1 (ru) Набор, содержащий заменитель сыворотки и лабильные факторы
WO2012131733A3 (en) Media compositions for enriching cultures of stem cells
BR112015021189A2 (pt) métodos de banco de células de alta densidade
BR112013004616A2 (pt) diferenciação das células tronco embrionárias humanas
BR112015022529A2 (pt) meios de cultura de células e processos de produção de anticorpo
MX2015004027A (es) Composiciones y metodos para producir glucoproteinas.
EP2582792A4 (en) HEART OF CARDIOMYOCYTES WITH DIALYSATED SERUM
MY184796A (en) Method for manufacturing ciliary marginal zone-like structure
JP2016500260A5 (pt)
RU2016150687A (ru) Способ получения стволовых клеток с индуцированной плюрипотентностью из мезенхимальных стволовых клеток путем использования фракции флоротаннина
JP2010166901A5 (pt)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: KEIO UNIVERSITY (JP) , DAIICHI SANKYO COMPANY, LIM

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: DAIICHI SANKYO COMPANY, LIMITED (JP) , HEARTSEED I

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/07/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2633 DE 22/06/2021, QUANTO AO ITEM (73) ENDERECO DO TITULAR.